Unicycive Therapeutics, Inc.
UNCY
$4.44
-$0.31-6.53%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -1,231.05% | 102.65% | -425.51% | -141.56% | 147.01% |
| Total Depreciation and Amortization | 2.22% | 0.75% | 8.94% | 208.85% | -139.79% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 102.53% | -159.24% | 1,243.69% | 92.89% | -231.14% |
| Change in Net Operating Assets | -26.60% | -207.11% | 141.21% | -3,924.07% | -94.29% |
| Cash from Operations | 5.43% | -35.97% | 29.23% | -46.42% | 2.12% |
| Capital Expenditure | 62.50% | 27.27% | 8.33% | -20.00% | -233.33% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 62.50% | 27.27% | 8.33% | -20.00% | -233.33% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 306.09% | 308.49% | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -100.00% |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | 100.00% | -- |
| Other Financing Activities | -41.80% | 23.27% | -102.55% | -155.28% | 106.59% |
| Cash from Financing | 331.42% | 597.53% | 332.48% | 80.64% | -101.77% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 140.14% | -2.71% | 34.22% | -31.93% | -118.23% |